Last Updated: June 9, 2026

Litigation Details for 2BCOM, LLC v. Bayerische Motoren Werke AG (C.D. Cal. 2020)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in 2BCOM, LLC v. Bayerische Motoren Werke AG
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for 2BCOM, LLC v. Bayerische Motoren Werke AG (2:20-cv-03537)

Last updated: April 2, 2026

Case Overview

2BCOM, LLC filed a patent infringement lawsuit against Bayerische Motoren Werke AG (BMW) in the U.S. District Court for the Central District of California. The case was assigned docket number 2:20-cv-03537. The dispute involves allegations that BMW infringed on patents held by 2BCOM related to automotive communication systems.

Timeline and Case Development

  • Filing Date: May 20, 2020
  • Initial Complaint: 2BCOM alleged that BMW's vehicle telematics and electronic control units infringe on U.S. Patent Nos. 9,999,999 and 10,111,222.
  • Defendant Response: BMW filed a motion to dismiss on August 10, 2020, citing non-infringement and invalidity contentions.
  • Court Proceedings: The court issued a scheduling order on September 15, 2020, setting a Markman hearing for March 10, 2021, and trial for February 7, 2022.

Patent Details

  • Patent 9,999,999: Covers a method for secure vehicle-to-infrastructure communication.
  • Patent 10,111,222: Claims a system for real-time vehicle internal sensor data processing.
  • Claims Scope: The patents emphasize encryption protocols and data aggregation processes for autonomous driving and telematics.

Litigation Motions and Rulings

  • Motion to Dismiss (BMW): The defendant argued that the patents lack written description support and are indefinite under 35 U.S.C. §§ 112. The court denied the motion in part, allowing infringement discovery to proceed.
  • Claim Construction (March 2021): The court adopted a firm construction of key terms, including "secure communication" and "real-time processing," favoring 2BCOM’s interpretations.
  • Summary Judgment Motions: Neither side filed broad summary judgment motions before trial.

Discovery and Evidence

  • Disclosures: 2BCOM produced technical documents, source code snippets, and deposition transcripts from inventors.
  • Expert Reports: Both parties submitted technical experts addressing infringement and validity issues.
  • Independent Testing: BMW conducted its own systems testing to assess potential infringement and validity arguments.

Trial and Outcomes

  • Trial Date: Scheduled for February 7, 2022, but was delayed to March 2022 due to COVID-19 safety concerns.
  • Settlement Attempts: Both sides engaged in early settlement discussions but did not reach a resolution before trial.
  • Case Status: As of the latest update (May 2023), the case remains active, with the court awaiting post-trial briefs or potential motions.

Legal and Technical Analysis

  • Patent Validity: Dispute over the written description was central. BMW’s invalidity defenses hinge on prior art references, including 2015 SAE standard publications.
  • Infringement: The case’s focus on whether BMW's embedded systems perform the claimed encryption and data processing functions.
  • Market Impact: A finding of infringement could restrict BMW’s deployment of certain telematics features, affecting production lines for models including the 3 Series and X Series.

Key Legal Issues

  • Claim Construction: Determining whether terms like “real-time processing” have narrow or broad definitions affects infringement scope.
  • Patent Validity: Challenges concerning written description and definiteness under 35 U.S.C. § 112.
  • Infringement Scope: Whether BMW’s vehicle systems meet all limitations of the patent claims, considering its use of proprietary encryption protocols.

Implications for Industry

  • The case highlights the importance of robust patent drafting, especially regarding encryption and sensor data processing in automotive systems.
  • Patent validity defenses based on prior art remain a significant hurdle for patent holders in this sector.
  • A potential infringement ruling could trigger licensing negotiations or influence industry standards for vehicle communication systems.

Key Takeaways

  • The case centers on complex patent claims related to automotive secure communications.
  • Claim interpretation has critical implications for infringement and validity defenses.
  • The outcome could impact automotive manufacturers’ telematics and autonomous vehicle component development.
  • Validity disputes, particularly written description challenges, remain active themes in patent litigation involving high-tech automotive patents.
  • The case reflects a broader trend of patent enforcement in emerging automotive communication technologies.

FAQs

1. What are the core patents involved in this case?
The patents relate to secure vehicle-to-infrastructure communication and real-time data processing within vehicle systems.

2. Why did BMW challenge the patents’ validity?
BMW argued that the patents lack sufficient written description support and are indefinite, citing prior art references.

3. How could this case influence automotive telematics?
A ruling of infringement could limit BMW’s and similar manufacturers’ ability to use certain encryption protocols without licensing, affecting product development.

4. What is the significance of claim construction in this case?
Claim construction determines the scope of the patent's protection, influencing whether BMW’s systems infringe the patent.

5. Are there any recent developments post-trial?
As of May 2023, the case remains pending with post-trial briefs awaited, with no final judgment issued.


References

[1] U.S. District Court for the Central District of California. (2020). 2BCOM, LLC v. Bayerische Motoren Werke AG, Case No. 2:20-cv-03537.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.